On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus type 5 vector) as a booster shot. The free booster immunization program indicates that the vaccine is currently unavailable for basic immunization.
Eligibility Criteria
Eligible for the one-shot booster immunization program are individuals aged 18 and above who have received inactivated vaccines manufactured by the Beijing Institute of Biological Products Co Ltd and Wuhan Institute of Biological Products Co Ltd, or intramuscular recombinant COVID-19 vaccines (adenovirus type 5 vector) by Sinovac Research & Development Co. Ltd within the past six months. Eligible citizens can pre-book online via the Health Cloud APP starting October 25. Existing booster immunization policies for expatriates and compatriots from Hong Kong, Macao, and Taiwan residing in Shanghai remain in place.
Vaccine Background
Convidecia (recombinant novel coronavirus vaccine, adenovirus type 5 vector), co-developed by Chinese firm CanSino Biologics (HKG: 6185) and the China Academy of Military Medical Sciences, obtained military special need drug approval in June 2020. The vaccine is known for its one-shot regimen and can be stored at temperatures between -2°C to -8°C, enhancing accessibility for developing countries. Convidecia has gained market entry in over 10 countries, including China, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Pakistan, United Arab Emirates, Indonesia, and Malaysia. Partnerships for local fill-and-finish operations have also been established in Mexico, Pakistan, and Malaysia.
Inhalable Vaccine Development
The inhalable recombinant COVID-19 vaccine (type 5 adenovirus vector), co-developed with the Academy of Military Medical Sciences, received clinical trial approval in China in March 2022. Last month, the vaccine became the first of its kind globally after gaining conditional approval from the National Medical Products Administration (NMPA).-Fineline Info & Tech
